Sera Prognostics appoints Mark Capone to Board of Directors effective July 1, 2026

SERA PROGNOSTICS, INC.

Mark Capone appointed as Class II director effective July 1, 2026, and to the Compensation Committee.
Capone is former CEO of Myriad Genetics with 40+ years in diagnostics and life sciences.
Initial equity award of $167,072 (or 150,000 option equivalents) granted July 10, 2026, with multi-year vesting.
Annual equity awards of $88,359 (or 75,000 option equivalents) after each annual meeting, vesting over one year.
Board determined Capone is independent under Nasdaq rules.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.